Inmagene LLC

Atopic Dermatitis

Inmagene LLC focuses its clinical research on atopic dermatitis, with an emphasis on adult patients living with moderate-to-severe disease. Its studies examine treatment effects on eczema burden and clinical signs of skin inflammation.

  • Atopic dermatitis
  • Moderate-to-severe eczema
  • Inflammatory skin disease

The sponsor’s research activity in this area reflects a concentrated interest in dermatologic conditions where control of disease activity and symptom reduction are central therapeutic goals.

Dermatology Safety and Tolerability

The clinical program also places strong attention on safety and tolerability in adults with atopic dermatitis, including the monitoring of treatment-emergent adverse events in a dermatology setting.

  • Adverse events
  • Safety assessment
  • Tolerability evaluation

This area of interest highlights the sponsor’s involvement in therapeutic development for chronic skin disease where both efficacy and patient safety are key clinical priorities.

Immunology-Driven Skin Disease

Inmagene LLC’s research landscape extends into immune-mediated skin disease, with a therapeutic focus on conditions shaped by persistent inflammatory activity and immune dysregulation.

  • Immune-mediated inflammation
  • Chronic inflammatory dermatoses
  • Skin immune modulation

Its funded trials reflect interest in therapies aimed at modifying the underlying inflammatory features of atopic dermatitis.

Adult Therapeutic Development

The sponsor’s clinical activity is centered on adult participants, supporting research in a population with ongoing treatment needs and long-term disease management challenges.

  • Adult dermatology
  • Chronic disease management
  • Symptom control

This focus aligns with therapeutic development for persistent skin inflammation in adults requiring effective management of disease activity and associated symptoms.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of IMG-007 injection to treat moderate to severe atopic dermatitis in adults

    Not yet recruiting

    2 1
    Investigated drugs:
    Czechia Germany Hungary Poland Spain
  • Study on the Safety and Effects of IMG-007 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany Poland